Senseye

Senseye

Smartphone-based PTSD diagnostics via eye biomarkers

Overview

Senseye creates a Software as a Medical Device for mental health diagnosis, starting with PTSD. It uses a smartphone app to record eye responses with the front camera while users perform simple visual tasks, extracting digital biomarkers from pupil gaze and iris biomechanics. A proprietary machine learning algorithm analyzes these signals to produce a diagnostic report with a severity score within minutes, without specialized hardware. Its goal is to replace subjective self-reports and expand to a broader panel of mental health disorders (like MDD and GAD) for baseline assessment and monitoring of treatment outcomes.

About Senseye

Simplify's Rating
Why Senseye is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

AI & Machine Learning

Healthcare

Company Size

11-50

Company Stage

Series A

Total Funding

$8M

Headquarters

Austin, Texas

Founded

2015

Get referred to Senseye

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • A 2026 peer-reviewed study found smartphone pupillometry differentiates PTSD using a standard iPhone.
  • ClinicalTrials.gov now shows recruiting Phase 3 validation across six sites and three sponsors.
  • Topcon's Harmony integration can place Senseye inside ophthalmology workflows by 2026.

What critics are saying

  • REVEAL's 1,900-patient Phase 3 readout is due October 2026; failure kills FDA momentum.
  • Senseye depends on one biomarker modality, and specificity against GAD and MDD remains unproven.
  • If the algorithm underperforms versus CAPS-5-R, clinicians reject it and payers never reimburse.

What makes Senseye unique

  • Senseye uses standard iPhone pupil biometrics to score PTSD severity in minutes.
  • Its 2026 whitepaper says the platform targets FDA-regulated medical use.
  • Topcon Healthcare invested September 9, 2025, linking Senseye to ocular-data distribution.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$8M

Below

Industry Average

Funded Over

4 Rounds

Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Below Average

Industry standards

$15M
$3.5M
Senseye
$5M
ByteDance
$8.2M
Discord
$15M
Canva
$30M
Kalshi

Benefits

Stock Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

Commuter Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

↓ -2%

1 year growth

↓ -7%

2 year growth

↓ -2%
Topcon Healthcare, Inc.
Sep 9th, 2025
Topcon Healthcare, Inc. makes Strategic Investment in Senseye, Inc. to Advance Mental Health Diagnostics Through Ocular Biomarkers

Topcon Healthcare, Inc. makes strategic investment in Senseye, Inc. to advance mental health diagnostics through ocular biomarkers.

Eyewire
Sep 9th, 2025
Topcon Invests in Senseye for Eye-Based Mental Health Diagnostics

Topcon Healthcare has invested in Senseye, which is developing a mental health diagnostic platform using ocular biomarkers. Senseye's technology employs AI to analyze eye movements via smartphone cameras, aiding in diagnosing PTSD, MDD, and GAD. This investment marks Topcon's first foray into mental health, aiming to integrate Senseye's tech into its Harmony platform for a comprehensive view of patients' health. Financial terms were not disclosed.

Eyewire
Sep 9th, 2025
Topcon Healthcare Invests in Senseye to Advance Mental Health Diagnostics Through the Eye - Eyewire+

Topcon Healthcare announced a strategic investment in Senseye, which is developing a mental health diagnostic platform powered by ocular biomarke

LSE Europe Summit
Apr 18th, 2025
AI in Diagnostics: Opportunities for Transformation

For Zakariaie, whose company Senseye is developing AI tools for behavioral health, the key is intentional dataset design.

Trending Topics
Nov 28th, 2023
Ai Is So Much More Than Just Chatgpt – And This Investor Proves It

Kinled is renowned as a life sciences and financial technology investor, with a portfolio of over 125 investments. Within their portfolio are nearly 50 companies specialised in cutting edge digital technology. The advent of AI has altered the investment strategy of Patrick Aisher, Chairman of Hong Kong-based Kinled Holding Limited, who has established a global investment network. “Approximately 25% of our technology portfolio is directly involved in Artificial Intelligence applications”, says Aisher. “In reality, the use of massive computational power in life sciences and molecular drug discovery has been standard for many years, and this type of approach is now being applied to other industries. Kinled was an early investor in the first-ever FDA-approved AI diagnostic platform, and now has AI and machine-learning investments across multiple industries.”

Recently Posted Jobs

Sign up to get curated job recommendations

Senseye is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →